GO:0004833 L-tryptophan 2,3-dioxygenase activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0004833 describes the molecular function that catalyzes the reaction L-tryptophan + O2 = N-formyl-L-kynurenine, the first and rate-limiting step of the kynurenine pathway.
• This activity is mediated by heme-dependent dioxygenases, principally TDO2 in the liver and IDO1/IDO2 in immune and tumor cells, which share the same GO term but differ in tissue distribution and regulation.
• The kynurenine pathway downstream of GO:0004833 produces neuroactive and immunomodulatory metabolites that influence aging, depression, inflammatory bowel disease, and cancer progression.
• Tryptophan depletion by this activity can cause tryptophan-to-phenylalanine substitutants in proteins, linking the enzyme to proteome-level quality control.
• Experimental study of GO:0004833 relies on enzyme activity assays, knockout and point-mutation cell models, and metabolic profiling of tryptophan and kynurenine.
• CRISPR-based knockout, knock-in, and overexpression models enable causal dissection of TDO2 and IDO1 contributions to disease and therapy.
Description
L-tryptophan 2,3-dioxygenase activity (GO:0004833) is a molecular function that catalyzes the oxidative cleavage of the indole ring of L-tryptophan to form N-formyl-L-kynurenine, the committed step of the kynurenine pathway. This activity is essential for tryptophan catabolism and is carried out by heme-containing enzymes, most notably tryptophan 2,3-dioxygenase (TDO2) and indoleamine 2,3-dioxygenase 1 (IDO1) and 2 (IDO2). Because the kynurenine pathway generates metabolites that modulate immune responses, neuronal function, and tumor microenvironments, GO:0004833 sits at the interface of metabolism, immunology, and neuroscience. Researchers study this activity to understand how tryptophan flux is redirected in disease and to identify therapeutic opportunities. The reaction is also relevant to protein synthesis because excessive tryptophan consumption can alter amino acid availability and lead to translational errors such as tryptophan-to-phenylalanine substitutions. In this article, we integrate the QuickGO definition with verified literature to outline the mechanism, key genes, disease links, and experimental models for GO:0004833.
L-tryptophan 2,3-dioxygenase activity At A Glance
| GO ID | GO:0004833 |
|---|---|
| GO term | L-tryptophan 2,3-dioxygenase activity |
| Ontology | molecular_function |
| Synonym | indolamine 2,3-dioxygenase activity; indoleamine-pyrrole 2,3-dioxygenase activity; L-tryptophan:oxygen 2,3-oxidoreductase (decyclizing); L-tryptophan pyrrolase activity; TDO; tryptamin 2,3-dioxygenase activity; tryptamine 2,3-dioxygenase activity; tryptophan 2,3-dioxygenase activity; tryptophan oxygenase activity; tryptophan peroxidase activity; tryptophan pyrrolase activity |
| Major function | Catalysis of L-tryptophan + O2 = N-formyl-L-kynurenine, the first and rate-limiting step of the kynurenine pathway. |
| Cofactor | Heme (iron protoporphyrin IX) is required for catalytic activity of TDO2 and IDO1. |
| Subcellular location | Predominantly cytosolic for IDO1 and TDO2 in mammalian cells. |
| Pathway | Kynurenine pathway of tryptophan catabolism, leading to kynurenine, kynurenic acid, quinolinic acid, and NAD+. |
| Representative genes | TDO2, IDO1, IDO2. |
What Is GO:0004833?
GO:0004833, L-tryptophan 2,3-dioxygenase activity, is defined as the catalysis of the reaction L-tryptophan + O2 = N-formyl-L-kynurenine. In other words, it is the enzyme activity that opens the indole ring of tryptophan by incorporating molecular oxygen, producing N-formyl-L-kynurenine, which is subsequently deformylated to kynurenine. This activity is synonymous with tryptophan oxygenase, tryptophan pyrrolase, and indoleamine 2,3-dioxygenase activity, reflecting historical names for the same catalytic function.
Why Is L-tryptophan 2,3-dioxygenase activity Important in Cell Biology?
GO:0004833 is important because it governs the first committed step of tryptophan catabolism through the kynurenine pathway, a metabolic route that influences immune tolerance, neuronal excitability, and tumor immune evasion. Dysregulation of this activity has been implicated in obesity-related metabolic inflammation, aging, depression associated with inflammatory bowel disease, and cancer progression. Moreover, because tryptophan is an essential amino acid, its depletion by high GO:0004833 activity can affect protein synthesis and lead to translational substitutions, adding a proteome-level dimension to its biological impact. Understanding this activity is therefore central to both basic metabolism research and therapeutic development.
• Rate-limiting step of the kynurenine pathway, controlling flux to neuroactive and immunomodulatory metabolites.
• Central to immune tolerance and tumor immune escape through kynurenine-mediated aryl hydrocarbon receptor activation.
• Linked to aging processes via IDO1 and kynurenine pathway regulation.
• Implicated in depression and gut-brain axis dysfunction in inflammatory bowel disease.
• Contributes to obesity-related metabolic inflammation through altered IDO1 activity.
• Tryptophan depletion by this activity can cause tryptophan-to-phenylalanine substitutants in proteins.
• Expressed in peripheral tissues such as skin, indicating broader physiological roles beyond liver.
• Target for small-molecule inhibitors in immuno-oncology and neuropsychiatry.
• Enzyme activity can be measured in breast cancer cells, highlighting relevance to cancer metabolism.
• Provides a mechanistic link between amino acid metabolism and protein quality control.
What Happens During L-tryptophan 2,3-dioxygenase activity?
Substrate binding and oxygen activation
In simple terms: The enzyme grabs tryptophan and oxygen to start the reaction.
The catalytic cycle begins with binding of L-tryptophan and molecular oxygen to the heme-containing active site of TDO2 or IDO1. The heme iron coordinates oxygen, enabling oxidative cleavage of the indole ring. This step is rate-limiting for the entire kynurenine pathway.
Formation of N-formyl-L-kynurenine
In simple terms: The enzyme opens the tryptophan ring to make a new molecule.
Oxidative cleavage of the indole ring yields N-formyl-L-kynurenine, the direct product of GO:0004833. This unstable intermediate is rapidly deformylated by kynurenine formamidase to produce kynurenine, which feeds downstream branches of the pathway.
Downstream kynurenine pathway flux
In simple terms: The product is converted into several signaling molecules.
Kynurenine is further metabolized to neuroactive compounds such as kynurenic acid and quinolinic acid, and to NAD+. The balance between these branches influences neuronal function, immune responses, and aging.
Tryptophan depletion and translational consequences
In simple terms: When tryptophan is used up, protein building can make mistakes.
High GO:0004833 activity can deplete intracellular tryptophan, leading to amino acid starvation and incorporation of phenylalanine at tryptophan codons, producing tryptophan-to-phenylalanine substitutants. This links the enzyme to proteome-level stress responses.
Key Genes Involved in GO:0004833 L-tryptophan 2,3-dioxygenase activity
The genes encoding enzymes with GO:0004833 activity are primarily TDO2, IDO1, and IDO2, which share the ability to catalyze the same reaction but differ in regulation and tissue distribution.
| Gene | Major Role | Research Relevance |
|---|---|---|
| TDO2 | Liver-enriched tryptophan 2,3-dioxygenase that catalyzes GO:0004833 | Metabolic studies, obesity, and systemic tryptophan homeostasis |
| IDO1 | Interferon-inducible indoleamine 2,3-dioxygenase that catalyzes GO:0004833 | Immune tolerance, cancer immunotherapy, and aging research |
| IDO2 | Indoleamine 2,3-dioxygenase 2 with reported dioxygenase activity | Comparative enzymology and immune regulation |
| KYNU | Kynureninase downstream of GO:0004833 product | Neuroactive metabolite balance in depression and IBD |
| KMO | Kynurenine 3-monooxygenase, directs flux to quinolinic acid | Neurodegeneration and neuroinflammation models |
| KAT1 | Kynurenine aminotransferase, produces kynurenic acid | Neuroprotection studies |
| QPRT | Quinolinate phosphoribosyltransferase, NAD+ synthesis | Metabolic and aging research |
| AHR | Aryl hydrocarbon receptor activated by kynurenine | Tumor immunology and xenobiotic responses |
| IFNG | Interferon gamma induces IDO1 expression | Inflammation and immune checkpoint studies |
| IL6 | Inflammatory cytokine linked to IDO1 induction | Obesity and chronic inflammation models |
| TNF | Tumor necrosis factor, modulates kynurenine pathway | IBD and depression research |
| TPH1 | Tryptophan hydroxylase, competes for tryptophan | Serotonin vs kynurenine flux studies |
| SLC7A5 | L-type amino acid transporter for tryptophan uptake | Tryptophan transport in cancer cells |
| SLC1A5 | Glutamine transporter influencing tryptophan availability | Metabolic flux experiments |
| GCN2 | Amino acid sensor activated by tryptophan depletion | Integrated stress response studies |
| ATF4 | Transcription factor downstream of GCN2 | Translational control and substitutant research |
| EIF2AK4 | Gene encoding GCN2, senses uncharged tRNA | Protein synthesis stress models |
How Is L-tryptophan 2,3-dioxygenase activity Regulated?
GO:0004833 activity is regulated at multiple levels. TDO2 is primarily controlled by substrate availability and hormonal signals, whereas IDO1 is strongly induced by interferon gamma and other inflammatory cytokines. In obesity, chronic inflammation alters IDO1 activity, contributing to metabolic dysfunction. The kynurenine pathway is also influenced by aging, with IDO1 playing a role in age-related immune regulation. Additionally, tryptophan depletion caused by high enzyme activity activates the integrated stress response via GCN2, which phosphorylates eIF2alpha and modulates translation. This feedback links GO:0004833 to cellular amino acid sensing and proteome quality control.
L-tryptophan 2,3-dioxygenase activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IDO1 | Cancer immune evasion and aging | IDO1 knockout tumor cells and syngeneic mouse models |
| TDO2 | Obesity and metabolic inflammation | TDO2 knockout hepatocytes and diet-induced obesity models |
| KYNU | Depression in inflammatory bowel disease | KYNU knockdown intestinal epithelial cells |
| AHR | Tumor-promoting ligand response | AHR knockout cancer cell lines |
| GCN2 | Tryptophan depletion stress | GCN2 knockout cells with substitutant analysis |
Cancer and immune evasion
Tumors can upregulate IDO1 and TDO2 to deplete tryptophan and produce kynurenine, which activates the aryl hydrocarbon receptor and promotes immune tolerance. This mechanism supports tumor growth and resistance to immunotherapy, making GO:0004833 a target for small-molecule inhibitors.
Neuropsychiatric and neurodegenerative disorders
Dysregulated kynurenine pathway flux downstream of GO:0004833 is implicated in depression, especially in the context of inflammatory bowel disease, and in aging-related neurodegeneration. Shifts toward neurotoxic quinolinic acid or neuroprotective kynurenic acid can influence neuronal survival and mood.
Metabolic and inflammatory diseases
In obesity, altered IDO1 activity and kynurenine pathway metabolites contribute to chronic low-grade inflammation and insulin resistance. The gut-brain axis further links tryptophan catabolism to inflammatory bowel disease and depression.
Protein synthesis stress and substitutants
Excessive tryptophan consumption by GO:0004833 can cause tryptophan-to-phenylalanine substitutions in nascent proteins, potentially generating neoepitopes and affecting protein function. This connects the enzyme to translational fidelity and cancer immunology.
From L-tryptophan 2,3-dioxygenase activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of TDO2 alter systemic tryptophan levels? | TDO2 knockout cell line or mouse model |
| Does IDO1 point mutation affect catalytic activity? | IDO1 point-mutation knock-in cells |
| Can kynurenine production be tracked in live cells? | Tagged knock-in of IDO1 with fluorescent reporter |
| Does overexpression of IDO1 induce immune tolerance? | IDO1 overexpression in cancer cells |
| Which genes mediate tryptophan depletion stress? | CRISPR library screening under low tryptophan |
| Is TDO2 activity required in skin? | TDO2 knockout keratinocytes |
How to Study the L-tryptophan 2,3-dioxygenase activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Enzyme activity assay | Conversion of tryptophan to kynurenine | Quantifying GO:0004833 in cell lysates |
| LC-MS/MS metabolomics | Tryptophan and kynurenine pathway metabolites | Pathway flux in disease models |
| RNA-seq | Expression of TDO2, IDO1, and related genes | Transcriptional regulation studies |
| Proteomics | Protein abundance and substitutants | Translational stress analysis |
| CRISPR knockout | Loss-of-function phenotypes | Causal gene validation |
| CRISPR knock-in | Tagged or mutant enzyme expression | Live-cell imaging and activity tracking |
| Co-culture immune assays | T-cell suppression by kynurenine | Immuno-oncology research |
Enzyme activity assays
GO:0004833 activity can be measured spectrophotometrically by monitoring the formation of N-formyl-L-kynurenine or kynurenine at absorbance around 360 nm. These assays are used in tissue lysates and purified enzyme preparations to quantify catalytic rates.
Metabolic profiling
LC-MS/MS-based metabolomics quantifies tryptophan, kynurenine, kynurenic acid, and quinolinic acid, providing a readout of pathway flux downstream of GO:0004833. This approach is essential in obesity, IBD, and neuropsychiatric studies.
Transcriptomic and proteomic analysis
RNA-seq and proteomics reveal changes in TDO2, IDO1, and downstream pathway genes, as well as global effects on translation such as tryptophan-to-phenylalanine substitutants. These methods link enzyme activity to cellular phenotypes.
CRISPR-based genetic models
Knockout, knock-in, and overexpression models allow causal testing of specific genes in the GO:0004833 pathway. For example, IDO1 knockout cancer cells show altered immune responses in co-culture assays.
How CRISPR Can Be Used to Study GO:0004833 L-tryptophan 2,3-dioxygenase activity
Knockout
CRISPR knockout of TDO2 or IDO1 eliminates GO:0004833 activity, allowing researchers to test its role in tryptophan depletion, kynurenine production, and immune modulation. Knockout cell lines are valuable for validating inhibitor specificity and for metabolic studies.
Point Mutation
Point mutations in the catalytic domain of IDO1 or TDO2 can be introduced to dissect heme binding, substrate recognition, and catalytic residues. Such models help distinguish enzyme activity from scaffolding functions.
Knock-in
Knock-in of fluorescent or affinity tags into endogenous TDO2 or IDO1 loci enables real-time tracking of enzyme localization and interaction partners. Tagged knock-in models are also useful for chromatin immunoprecipitation and proteomics.
Overexpression
Overexpression of IDO1 or TDO2 in cancer or immune cells creates models of tryptophan depletion and kynurenine accumulation, mimicking tumor microenvironments. These models are used to test immunotherapies and metabolic interventions.
How EDITGENE Supports L-tryptophan 2,3-dioxygenase activity Research
Researchers studying L-tryptophan 2,3-dioxygenase activity-related genes often need to determine whether a candidate gene is causally involved in tryptophan catabolism, immune regulation, or disease progression. EDITGENE provides a comprehensive suite of CRISPR services to generate precisely engineered cell models for such investigations.
Contact EDITGENE today to design your custom CRISPR model for L-tryptophan 2,3-dioxygenase activity research.
Frequently Asked Questions About L-tryptophan 2,3-dioxygenase activity
What is L-tryptophan 2,3-dioxygenase activity?
It is the enzyme activity defined by GO:0004833 that catalyzes the conversion of L-tryptophan and oxygen to N-formyl-L-kynurenine, the first step of the kynurenine pathway.
What genes are involved in L-tryptophan 2,3-dioxygenase activity?
The main genes are TDO2, IDO1, and IDO2, which encode heme-containing enzymes with this activity.
What is the difference between TDO2 and IDO1?
TDO2 is primarily expressed in the liver and regulated by substrate availability, while IDO1 is induced by interferon gamma in immune and tumor cells.
How is GO:0004833 activity measured?
It is commonly measured by enzyme assays that detect kynurenine formation or by LC-MS/MS metabolomics of tryptophan and its metabolites.
What diseases are linked to L-tryptophan 2,3-dioxygenase activity?
It has been implicated in cancer immune evasion, depression, inflammatory bowel disease, obesity, and aging.
Can CRISPR be used to study GO:0004833?
Yes, CRISPR knockout, knock-in, and overexpression models are widely used to study the function of TDO2 and IDO1.
What is the role of kynurenine in cancer?
Kynurenine produced by GO:0004833 activates the aryl hydrocarbon receptor, promoting immune tolerance and tumor growth.
Does tryptophan depletion affect protein synthesis?
Yes, excessive tryptophan consumption can lead to tryptophan-to-phenylalanine substitutions in proteins, activating stress responses.
Which tissues express TDO2?
TDO2 is highly expressed in the liver but has also been detected in skin and other peripheral tissues.
How does IDO1 contribute to aging?
IDO1 and kynurenine pathway metabolites are involved in age-related immune regulation and inflammation.
Conclusion
GO:0004833, L-tryptophan 2,3-dioxygenase activity, is a central molecular function that controls the first step of tryptophan catabolism through the kynurenine pathway. Its dysregulation is linked to cancer, neuropsychiatric disorders, metabolic inflammation, and aging, making it a high-value target for both basic and translational research. Advances in CRISPR-based models and metabolic profiling continue to clarify how TDO2 and IDO1 contribute to health and disease. Researchers can leverage these tools to dissect mechanism and develop new therapeutic strategies.
References
- 1. Engin AB et al.. 2024. Tryptophan Metabolism in Obesity: The Indoleamine 2,3-Dioxygenase-1 Activity and Therapeutic Options.. Adv Exp Med Biol 1460:629-655 PMID: 39287867
- 2. Salminen A. 2022. Role of indoleamine 2,3-dioxygenase 1 (IDO1) and kynurenine pathway in the regulation of the aging process.. Ageing Res Rev 75:101573 PMID: 35085834
- 3. Opitz CA et al.. 2011. An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor.. Nature 478(7368):197-203 PMID: 21976023
- 4. Chen LM et al.. 2021. Tryptophan-kynurenine metabolism: a link between the gut and brain for depression in inflammatory bowel disease.. J Neuroinflammation 18(1):135 PMID: 34127024
- 5. Pataskar A et al.. 2022. Tryptophan depletion results in tryptophan-to-phenylalanine substitutants.. Nature 603(7902):721-727 PMID: 35264796
- 6. Naito J et al.. 1989. Tryptophan 2,3-dioxygenase activity in rat skin.. Arch Biochem Biophys 270(1):236-41 PMID: 2930188
- 7. Lubis AB et al.. 2026. Monooxygenase Activity of Indoleamine 2,3-Dioxygenase.. J Am Chem Soc 148(6):6178-6187 PMID: 41640298
- 8. Travers MT et al.. 2004. Indoleamine 2,3-dioxygenase activity and L-tryptophan transport in human breast cancer cells.. Biochim Biophys Acta 1661(1):106-12 PMID: 14967480
